Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has agreed to acquire Switzerland-based Nycomed, excluding US dermatology business, for EUR9.6bn on cash-free, debt-free basis.
Subscribe to our email newsletter
The acquisition will allow Takeda to add roflumilast franchise (Daxas; trade name in Europe), indicated as the treatment for chronic obstructive pulmonary disease (COPD), into its product portfolio which is expected to be a major source of revenue growth.
Takeda will also enhance its development expertise and commercialization capability in Europe and emerging markets, through this acquisition.
Takeda president and CEO Yasuchika Hasegawa said Nycomed enables Takeda to maximize the value of their portfolio and gives them an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales.
The transaction, which is expected to be closed within 90 to 120 days, will make Nycomed as the wholly subsidiary of Takeda.